PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 67.9717

Change

-0.23 (-0.34)%

Market Cap

N/A

Volume

4.32K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.59 (-1.09%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.66 (-0.95%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.90 (-0.83%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-0.38 (-0.41%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.17 (+0.75%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.06 (+0.18%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.77 (-0.76%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.18 (+0.59%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.34 (+0.54%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.45 (+2.08%)

USD 6.89M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.17% 24% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.17% 24% F 46% F
Trailing 12 Months  
Capital Gain 5.15% 71% C- 48% F
Dividend Return 0.05% 13% F N/A F
Total Return 5.20% 71% C- 36% F
Trailing 5 Years  
Capital Gain 20.65% 43% F 59% D-
Dividend Return 0.13% 11% F N/A F
Total Return 20.78% 43% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 5.09% 57% F 51% F
Dividend Return 5.11% 52% F 43% F
Total Return 0.01% 11% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 20.38% 48% F 53% F
Risk Adjusted Return 25.07% 52% F 39% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.